tiprankstipranks
Advertisement
Advertisement

SLN Stock Latest News

Silence Therapeutics 13M share Secondary priced at $13.50
The FlySilence Therapeutics 13M share Secondary priced at $13.50
2d ago
SLN
Silence Therapeutics 13M share Secondary priced at $13.50
PremiumThe Fly
Silence Therapeutics 13M share Secondary priced at $13.50
2d ago
SLN
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
2d ago
WU
SLN
Silence Therapeutics Announces Major ADS Public Offering
PremiumCompany Announcements
Silence Therapeutics Announces Major ADS Public Offering
6d ago
8K
SLN
Silence Therapeutics price target raised to $32 from $25 at Morgan Stanley
PremiumThe Fly
Silence Therapeutics price target raised to $32 from $25 at Morgan Stanley
8d ago
SLN
Silence Therapeutics files to sell $150M in ADS’s
PremiumThe FlySilence Therapeutics files to sell $150M in ADS’s
8d ago
SLN
Silence Therapeutics Reports Positive Phase 2 Divesiran Data
Premium
Company Announcements
Silence Therapeutics Reports Positive Phase 2 Divesiran Data
9d ago
8K
SLN
Silence announces results from Phase 2 SANRECO trial met primary endpoint
Premium
The Fly
Silence announces results from Phase 2 SANRECO trial met primary endpoint
9d ago
SLN
Silence Therapeutics reports Q2 EPS (9c), consensus (17c)
PremiumThe Fly
Silence Therapeutics reports Q2 EPS (9c), consensus (17c)
9d ago
SLN
Silence Therapeutics participates in a conference call with Cantor
PremiumThe Fly
Silence Therapeutics participates in a conference call with Cantor
1M ago
SLN
Silence Therapeutics participates in a conference call with William Blair
PremiumThe Fly
Silence Therapeutics participates in a conference call with William Blair
1M ago
SLN
Blair adds American Express, Oracle to Conviction List in monthly update
PremiumThe Fly
Blair adds American Express, Oracle to Conviction List in monthly update
2M ago
P
CW
Cantor starts ‘materially undervalued’ Silence Therapeutics at Overweight
PremiumThe FlyCantor starts ‘materially undervalued’ Silence Therapeutics at Overweight
2M ago
SLN
Silence Therapeutics initiated with an Overweight at Cantor Fitzgerald
Premium
The Fly
Silence Therapeutics initiated with an Overweight at Cantor Fitzgerald
2M ago
SLN
Silence Therapeutics Updates Strategy and siRNA Pipeline
Premium
Company Announcements
Silence Therapeutics Updates Strategy and siRNA Pipeline
2M ago
8K
SLN
Silence Therapeutics Shareholders Approve All AGM Resolutions
PremiumCompany Announcements
Silence Therapeutics Shareholders Approve All AGM Resolutions
2M ago
8K
SLN
Silence Therapeutics Earns Buy Rating on Promising Divesiran Phase I Data and Best-in-Class Potential
PremiumRatings
Silence Therapeutics Earns Buy Rating on Promising Divesiran Phase I Data and Best-in-Class Potential
2M ago
SLN
Silence Therapeutics Highlights Positive Divesiran Phase 1 SANRECO Data
PremiumCompany Announcements
Silence Therapeutics Highlights Positive Divesiran Phase 1 SANRECO Data
2M ago
8K
SLN
Silence Therapeutics highlights follow-up data on divesiran at EHA 2026
PremiumThe Fly
Silence Therapeutics highlights follow-up data on divesiran at EHA 2026
2M ago
SLN
Silence Therapeutics Reaffirmed at Buy as Analyst Sees PV Program Driving Upside; $25 Price Target Maintained
PremiumRatingsSilence Therapeutics Reaffirmed at Buy as Analyst Sees PV Program Driving Upside; $25 Price Target Maintained
3M ago
SLN
Silence Therapeutics: Buy Rating Reiterated on Pipeline Catalysts and PV Potential; $25 Price Target Maintained
Premium
Ratings
Silence Therapeutics: Buy Rating Reiterated on Pipeline Catalysts and PV Potential; $25 Price Target Maintained
3M ago
SLN
Buy Rating Reiterated on Silence Therapeutics as Advancing RNAi Pipeline and 2026 Catalysts Support Unchanged $75 Price Target
Premium
Ratings
Buy Rating Reiterated on Silence Therapeutics as Advancing RNAi Pipeline and 2026 Catalysts Support Unchanged $75 Price Target
3M ago
SLN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >